Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7652W HIGH $13.02
Volume
1.70 K
Value Traded
1.68 K
Short % Float
0%
+4.46%Week
-99.88%5 Year
-99.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.67 M
EPS (TTM)
-12.58
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
0.00%
Institutions
0.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
VCNX Catalyst Timeline
Dated clinical, regulatory and corporate events for Vaccinex, Inc.
Past FDA Catalysts and PDUFA Decisions
How VCNX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-10-31 | Pepinemab | Phase 1b/2 data readout | Phase 1b/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every VCNX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pepinemab | head and neck cancer | 2025-05-27 | the addition of pepinemab to neoadjuvant immune checkpoint treatments did not compound toxicities, yet it enhanced TLS maturity that correlated with improved pathologic responseRead More | Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zauderer MauriceDirector, Officer (President and CEO), 10% Owner | Option | 38,610 176,748 held | $5.64 | 09/18/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in VCNX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VCNX for Q2 2026. | ||||
Ownership Trends
VCNX Short Interest
Shares sold short, counted twice a month.
0%
Short % of Float
of tradable shares sold short
2.1K
Shares Sold Short
-23.4% vs prior count
-
Days to Cover
trading days of normal volume to buy every short share back
662
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VCNX ranks across every disease it competes in
Competitive Position is a premium feature
See how VCNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVCNX News
VCNX▲ +28.7%on this news
Vaccinex Reports 2025 Annual Financial Results
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended Decem
Read more →VCNXVaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has
Read more →VCNX▲ +35%on this news
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Vaccinex, Inc. announced promising new clinical results for pepinemab, a treatment aimed at enhancing immunotherapy for head and neck cancer. The data, to be presented at the ASCO Annual Meeting, indicates that pepinemab can improve immune responses and pathologic outcomes in patients with resectable tumors. This treatment may offer a significant advantage for patients with traditionally resistant 'cold' tumors.
Read more →VCNXVaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
Vaccinex, Inc. announced new clinical data on pepinemab, revealing its unique mechanism to enhance immunotherapy at the AACR Annual Meeting. The data suggests that pepinemab induces the formation of mature lymphoid structures, which are associated with improved clinical outcomes in patients with metastatic melanoma and head and neck cancer. The findings highlight pepinemab's potential to convert cold tumors into hot immune centers, enhancing the effectiveness of checkpoint therapies.
Read more →VCNX▼ -9.7%on this news· ran to -25% by day 3
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Vaccinex, Inc. has announced its decision to delist its common stock from the Nasdaq Stock Market after trading was suspended in December 2024. The company plans to file a Form 25 with the SEC to formalize the delisting. Despite this setback, Vaccinex continues to focus on developing its lead product, pepinemab, for treating neurodegenerative diseases and cancer.
Read more →VCNX▼ -61.4%on this news
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
Vaccinex, Inc. has received a delisting notification from Nasdaq due to its failure to meet the required minimum stockholders' equity of $2.5 million. As a result, trading of its shares will be suspended on December 18, 2024. The company plans to continue trading on the OTC Markets Group under the symbol 'VCNX'.
Read more →VCNXVaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vaccinex, Inc. announced its financial results for Q3 2024 and provided updates on its Alzheimer's program. The company reported positive findings from its SIGNAL-AD trial, indicating that pepinemab may slow cognitive decline. Additionally, Vaccinex raised $2.15 million through a securities agreement but faces Nasdaq compliance challenges.
Read more →VCNXVaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex, Inc. announced several project agreements with notable companies to utilize its ActivMAb® technology for antibody discovery. The technology is designed to target complex antigens, enhancing both Vaccinex's and its partners' research capabilities. Additionally, Vaccinex will present successful antibody discovery data at the upcoming SITC meeting in Houston.
Read more →VCNXVaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Vaccinex, Inc. announced promising results from the Phase 2 KEYNOTE-B84 study, showing that neoadjuvant treatment with pepinemab enhances the effectiveness of immune checkpoint inhibitors in HPV-negative head and neck cancer. The data indicates that pepinemab may induce beneficial immune responses, leading to improved clinical outcomes. The findings will be presented at the Society for Immunotherapy of Cancer’s Annual Meeting.
Read more →VCNX▼ -28.1%on this newsshared move
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Vaccinex announced positive findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab in Alzheimer's disease. The study indicates that pepinemab treatment may inhibit biomarkers linked to cognitive decline and improve cognitive measures in patients with Mild Cognitive Impairment. Additionally, the treatment shows promise in addressing damage from alpha synuclein, potentially broadening its application to other neurodegenerative diseases.
Read more →VCNX▲ +24.2%on this news· ran to +39% by day 3
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it
Read more →VCNX▼ -14%on this news· ran to -25% by day 3
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
Vaccinex, Inc. has announced the immediate exercise of outstanding warrants, generating approximately $6.2 million in gross proceeds. The transaction involves the issuance of new warrants and is expected to close on September 18, 2024, pending customary conditions. This funding will support the company's ongoing clinical programs targeting neurodegenerative diseases and cancer.
Read more →VCNX▲ +9.9%on this news
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s disease. Our Company recently announced positive results of the phase 1b/2 study
Read more →VCNX▼ -36.7%on this news
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer’s disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington’s disease based on similarities to neuroimmune pat
Read more →VCNX▲ +12.5%on this news· ran to +29% by day 1
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it
Read more →VCNX▲ +7.6%on this news
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc.
Read more →VCNXVaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company p
Read more →VCNXVaccinex Reports 2023 Financial Results and Provides Corporate Update
Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer’s Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-s
Read more →VCNXVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, today announce
Read more →VCNX▲ +5.5%on this news
Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology
Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., Feb. 21, 2024 (GLOBE NEWS
Read more →About Vaccinex, Inc.
Headquarters1895 Mount Hope Avenue
Founded09-08-2018
BIOPHARMAWATCH ELITE
Trade the next VCNX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime